Yersinia pseudotuberculosis-based vaccines for plague and yersiniosis
基于假结核耶尔森氏菌的鼠疫和耶尔森氏菌疫苗
基本信息
- 批准号:9471106
- 负责人:
- 金额:$ 44.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-01 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdjuvantAnimalsAntigensAttentionAttenuatedBacterial VaccinesBiological WarfareBlood CirculationCellular ImmunityCessation of lifeDoseEconomic BurdenEnteralFleasFood SafetyHealthHeterophile AntigensHourHumanHumoral ImmunitiesImmune responseImmunityImmunizationImmunizeInfectionInnate Immune ResponseKnowledgeLegal patentLivestockModernizationMusNeedlesOnset of illnessOralOral AdministrationOutcomePasteurella pseudotuberculosisPersonsPlaguePlague VaccinePneumonic PlagueProductionPublic HealthRecombinantsRecording of previous eventsRiskRodentSafetySalmonella VaccinesSupplementationSymptomsSystemSystemic infectionUnited StatesVaccine ProductionVaccinesYersiniaYersinia enterocoliticaYersinia pestisZoonosesadaptive immune responseattenuationbasecostexperimental studyfoodborneimmunogenicityimprovedmortalitypandemic diseasepathogenpreventprotective efficacyvaccine candidatevaccine developmentvectorvector vaccineweapons
项目摘要
PROJECT SUMMARY
Yersinia pestis, the causative agent of plague, has profoundly shaped human history by causing an
estimated 200 million deaths amid three major pandemics. Considered to be a re-emerging pathogen, Y. pestis
remains a public health issue and is responsible for several thousand worldwide annual cases of plague.
Endemic plague foci persist through zoonotic circulation among rodent reservoir hosts and flea vectors. In
addition to natural flea-borne acquisition, Y. pestis has an extensive history of biological warfare manipulations
and is categorized as a prime threat for modern weaponization. Pneumonic plague, the most acute and
threatening manifestation, is highly contagious and easily transmitted from person-to-person through airborne
droplets, resulting in a rapid onset of disease and a mortality rate approaching 100% if treatment is delayed 24
hours beyond symptom onset. Currently, no licensed plague vaccines are available in the United States.
Yersiniosis refers to an enteric infection by species of the genus Yersinia. There are two subtypes
responsible for yersiniosis, Yersinia enterocolitica (Ye) and Yersinia pseudotuberculosis (Yptb). Ye and Yptb
are fecal-oral zoonotic pathogens which ciruclate among environmental and a broad range of animal
reserviors. Through incidental food-borne exposure, humans can develop yersiniosis, potentially culminating in
systemic infection and postinfectious extraintestinal sequelae. In addition to direct human health risks,
yersiniosis confers a considerable food-safety economic burden and is responsible for substantial livestock
production loss. However, limited attention has been devoted toward vaccine development for yersiniosis.
We have previously made substantial headway in the construction of a recombinant Yptb vector vaccine
candidate aimed at preventing both plague and yersiniosis. Based upon our established recombinant
attenuated Salmonella vaccine platform, a Yptb-based vaccine against plague and yersiniosis will impart
several key advantages including (1) needle-free oral administration, (1) low-cost vaccine production, and (3)
robust induction of humoral and cellular immune responses, and (4) human and environmental bait delivery.
Additionally, we strive to elicit protective immunity upon a single dose without adjuvant supplementation. We
previously demonstrated that immunization with attenuated Yptb strains elicits cross-protection against Y.
pestis and Ye. Furthermore, immunogenicity against Y. pestis is readily enhanced by type 3 secretion system
delivering heterologous antigens. Therefore, immunization with improved live attenuated Yptb strains shall
stimulate cross-protective immunity against Y. pestis causing plague, and Ye and Yptb causing yersinosis.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wei Sun其他文献
Wei Sun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wei Sun', 18)}}的其他基金
Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit
用于早期癌症评估的液体活检的竞争前合作:数据管理和协调单位
- 批准号:
10838127 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Post-GWAS Functional Genomics Analysis to Define Pathogenic Mechanisms for Pulmonary Arterial Hypertension
GWAS 后功能基因组学分析确定肺动脉高压的致病机制
- 批准号:
10524975 - 财政年份:2022
- 资助金额:
$ 44.36万 - 项目类别:
Yersinia Outer-Membrane-Vesicle Vaccines Against Pneumonic Plague
鼠疫耶尔森氏菌外膜囊泡疫苗
- 批准号:
10673295 - 财政年份:2022
- 资助金额:
$ 44.36万 - 项目类别:
Yersinia Outer-Membrane-Vesicle Vaccines Against Pneumonic Plague
鼠疫耶尔森氏菌外膜囊泡疫苗
- 批准号:
10555332 - 财政年份:2022
- 资助金额:
$ 44.36万 - 项目类别:
Yersinia Outer-Membrane-Vesicle Vaccines Against Pneumonic Plague
鼠疫耶尔森氏菌外膜囊泡疫苗
- 批准号:
10441853 - 财政年份:2022
- 资助金额:
$ 44.36万 - 项目类别:
Post-GWAS Functional Genomics Analysis to Define Pathogenic Mechanisms for Pulmonary Arterial Hypertension
GWAS 后功能基因组学分析确定肺动脉高压的致病机制
- 批准号:
10697364 - 财政年份:2022
- 资助金额:
$ 44.36万 - 项目类别:
Statistical Methods for T Cell Receptor (TCR) Analysis
T 细胞受体 (TCR) 分析的统计方法
- 批准号:
10620574 - 财政年份:2022
- 资助金额:
$ 44.36万 - 项目类别:
Statistical Genetics and Genomics for Epidemiologic Research
流行病学研究的统计遗传学和基因组学
- 批准号:
10426287 - 财政年份:2018
- 资助金额:
$ 44.36万 - 项目类别:
A novel computing framework to automatically process cardiac valve image data and predict treatment outcomes
一种新颖的计算框架,可自动处理心脏瓣膜图像数据并预测治疗结果
- 批准号:
9973167 - 财政年份:2018
- 资助金额:
$ 44.36万 - 项目类别:
Biomechanical study on aortic-mitral coupling in transcatheter aortic valve replacement
经导管主动脉瓣置换术中主动脉-二尖瓣耦合的生物力学研究
- 批准号:
9274379 - 财政年份:2016
- 资助金额:
$ 44.36万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 44.36万 - 项目类别: